We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Norway, Sweden Suspend Moderna Covid-19 Vaccine for Young Adults Over Side Effects

Norway, Sweden Suspend Moderna Covid-19 Vaccine for Young Adults Over Side Effects

October 7, 2021

Norway and Sweden are advising men younger than age 30 and all people under 18 years old to avoid taking the Moderna COVID-19 vaccine because of its rare association with myocarditis and endocarditis.

Analyses of reported adverse reactions from the U.S. “have suggested that myocarditis may be more frequent when using Moderna’s vaccine as a second dose” than using the Pfizer-BioNTech vaccine, “but the numbers have been small and therefore uncertain,” said Geir Bukholm, deputy director general at the Norwegian Institute of Public Health.

“New monitoring data from Ontario, Canada, substantiates that this observation is correct, and preliminary monitoring data from Norway, Sweden and other countries could indicate the same,” he said.

The varying reporting systems make it impossible to accurately determine the incidence of carditis, but “the side effect is rare and the absolute risk is still low,” he said.

Both of the mRNA vaccines used in the Norwegian coronavirus immunization program are “good and very effective, and provide a high degree of protection against severe COVID-19 infection,” although the Moderna vaccine does seem to provide marginally better protection against the Delta variant than the Pfizer vaccine, Bukholm said.

Nordic countries are collaborating on several large health registry analyses to detect and investigate rare COVID-19 vaccine side effects. While the combined data aren’t complete, Norwegian data suggest an increased incidence of cardiac inflammation after using the Moderna vaccine as a second dose.

Both governments already recommend the Pfizer vaccine for people aged 12-17 years. The new recommendation is that those under age 18 who received the Moderna first should have the Pfizer vaccine as their second dose. — Michele G. Sullivan

COVID-19

Upcoming Events

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

  • 08Mar

    Medical Device Cybersecurity: The Regulatory Landscape and How to Defend Your Practices During an Inspection

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Boston Scientific’s Single Use Ureteroscope Gets FDA Clearance

  • Gilead’s Trodelvy Gets Expanded Approval in Breast Cancer

  • AI Software to Improve Echocardiogram Images Gets FDA Clearance

  • Rocket Pharmaceuticals Gets RMAT Designation for Danon Disease Gene Therapy

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing